VBL Therapeutics

The company's lead product candidate is VB-111, a gene-based biologic agent designed to treat solid tumors. This agent is currently being developed for several types of cancer, including ovarian cancer, recurrent glioblastoma (a type of brain cancer), colon cancer, and thyroid cancer. VB-111 works by targeting the blood vessels that supply tumors, thereby inhibiting their growth.

In addition to VB-111, VBL Therapeutics is advancing two innovative programs based on their discovery of a protein called MOSPD2. This protein plays a crucial role in the movement of immune and tumor cells. The company is developing monoclonal antibodies (lab-made molecules that can mimic the immune system's ability to fight off harmful pathogens) targeting MOSPD2 for immune-inflammatory diseases and bi-specific antibodies for cancer. Bi-specific antibodies are engineered to bind to two different types of antigens, which can enhance their effectiveness in targeting diseases.

VBL Therapeutics operates in the biopharmaceutical market, serving patients with severe and often life-threatening conditions. The company's business model revolves around the development and commercialization of its proprietary treatments. Revenue is generated through the successful approval and sale of these therapies, as well as potential partnerships and licensing agreements with other pharmaceutical companies.